China's National Medical Products Administration has approved RemeGen's HER2-targeted antibody-drug conjugate disitamab vedotin for use in combination with toripalimab in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma. In the approval notice, HER2 expression was defined as immunohistochemistry 1+, 2+, or 3+. This is the fifth approved indication for disitamab vedotin in China and extends the drug's reach from previously cleared settings in gastric cancer, urothelial carcinoma, and breast cancer into a new first-line combination strategy for urothelial disease.
The approval was backed by the randomized, parallel-group, multicenter phase 3 RC48-C016 study conducted in China. The trial enrolled 484 patients across 74 study centers and evaluated disitamab vedotin plus toripalimab as first-line treatment for HER2-expressing urothelial carcinoma. In interim analyses previously announced by the company, the regimen met both major endpoints, progression-free survival and overall survival, with statistically significant and clinically meaningful benefit. As of March 31, 2025, median progression-free survival reached 13.1 months with the combination versus 6.5 months with chemotherapy, while median overall survival was 31.5 months versus 16.9 months. Objective response rate assessed by BIRC was 76.1% versus 50.2%, disease control rate was 91.4% versus 77.6%, and grade 3 or higher treatment-related adverse events occurred in 55.1% of patients compared with 86.9% in the chemotherapy arm.
Investigators described RC48-C016 as the first large randomized phase 3 trial to show that a HER2 ADC plus immunotherapy can significantly outperform standard platinum-based chemotherapy in the first-line treatment of Chinese patients with HER2-expressing metastatic urothelial carcinoma. The study was presented in the Presidential Symposium at the 2025 ESMO Congress and simultaneously published online in The New England Journal of Medicine. From a pipeline perspective, the approval further strengthens disitamab vedotin's differentiated positioning as the first domestically developed HER2 ADC in China, while signaling a broader move from later-line monotherapy into frontline combination therapy in urothelial cancer.